Biolinq raises $58m for glucose microsensor pivotal trial
Biolinq is eying an FDA application this year, according to CEO Richard Yang.
05 April 2024
05 April 2024
Biolinq is eying an FDA application this year, according to CEO Richard Yang.
The data is aimed to improve patient care, predict risk of cancer, detect cancer earlier, and guide treatment decisions.
NICE found that Smith+Nephew’s single-use negative pressure wound therapy results in fewer complications and is as cost-effective as the standard of care.
The director of BARDA’s medical countermeasures programs, Robert Johnson, PhD, talks about what the agency is planning to invest in the future.
The MAMMOMAT B.brilliant system is a complete rebuild mammography platform and improves patient comfort.
Paragonix's BAROguard system is designed to maintain donor lungs in optimal conditions during transport.
The Gen-3 HALO Clarity system features Nexalin's DIFS technology.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.